Treatment of Depression in Elderly Patients With and Without Dementia Disorders

Gottfries, C. G.; Karlsson, Ingvar; Nyth, Anna Lena

doi:10.1097/00004850-199206005-00006

Cited by 52 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is interesting that treatment of AD patients with the selective 5-HT reuptake inhibitor citalopram has been reported to result in improvement of depressive symptoms as well as agitation, anxiety. restlessness, and irritability (Gottfries et al, 1992), supporting the involvement of 5-HT in the behavioural problems of AD patients. The significant positive relationship between 5-HT concentration and ['H]paroxetine binding in control cases is consistent with both being markers, functional Data are mean ± SEM values.…”

Section: Discussionmentioning

confidence: 69%

Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication

Chen

Alder²,

Bowen³

et al. 1996

Journal of Neurochemistry

126

View full text Add to dashboard Cite

Presynaptic serotonergic markers, serotonin uptake sites, and concentrations of serotonin and 5-hydroxyindoleacetic acid were studied in the frontal and temporal cortex of 20 community-acquired cases of Alzheimer's disease and 16 controls matched for age, sex, postmortem delay, and storage. Clinical assessments, including behavioural symptoms, of the Alzheimer patients were made at 4-month intervals during life. There was a significant reduction in the number of serotonin uptake sites in Alzheimer cases in temporal but not frontal cortex. There was no significant alteration in the concentrations of serotonin or 5-hydroxyindoleacetic acid in either region. Alzheimer patients who had persistent depressive symptoms during life had significantly fewer serotonin uptake sites in both cortical areas compared with Alzheimer patients without these symptoms. In addition, Alzheimer patients who were receiving chronic neuroleptic medication had significantly lower concentrations of serotonin in frontal cortex and 5-hydroxyindoleacetic acid in temporal cortex than those patients not receiving such treatment. These data suggest previous studies that reported uniform serotonergic dysfunction may have been subject to unintentional selection of behaviourally disturbed Alzheimer cases or those receiving chronic neuroleptic medication. This study also provides a basis for the treatment of behaviourally disturbed Alzheimer patients with serotonomimetics.

show abstract

Section: Discussionmentioning

confidence: 69%

Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication

Chen

Alder²,

Bowen³

et al. 1996

Journal of Neurochemistry

126

View full text Add to dashboard Cite

show abstract

“…Dementia patients with depression are heavy consumers of medical, psychiatric and nursing home services (Kales et al, 1999;Koenig and Kuchibhatla, 1998), despite the fact that they often are not referred for necessary mental health services (Snowden et al, 1998). Moreover, depression in dementia is treatable (Reifler et al, 1986;Greenwald et al, 1989;Reifler et al, 1989;Reynolds et al, 1989;Gottfries et al, 1992;Volicer et al, 1994;Lyketsos et al, 2000;Streim et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

The prevalence, diagnosis and treatment of depression in dementia patients in chronic care facilities in the last six months of life

Evers

Samuels

Lantz

et al. 2002

Int J Geriat Psychiatry

View full text Add to dashboard Cite

Major depression was highly prevalent in both dementia patients and normal controls, indicating that depression is an important issue for the elderly in the last six months of life irrespective of cognitive status. Under-diagnosis of depression may be an important clinical issue. As physician diagnosis of depression has not improved with time, further physician training and/or awareness initiatives may be warranted. Depression, a treatable cause of excess morbidity and mortality, was undertreated in all groups studied. However, treatment rates may be improving. The prevalent use of anxiolytics and hypnotics for depressed patients is problematic.

show abstract

“…[5][6][7][8] Depression in patients with AD is associated with greater cortical loss of a marker of 5-HT neuronal terminals compared to AD patients without this symptom. 9 The clinical relevance of this finding is supported by clinical trials that demonstrate that 5-HT reuptake inhibitors such as citalopram 10 are able to improve mood and depressive symptoms in patients with AD.…”

mentioning

confidence: 91%

Cholinergic deficits contribute to behavioral disturbance in patients with dementia

Minger

Esiri²,

McDonald³

et al. 2000

Neurology

155

106

View full text Add to dashboard Cite

show abstract

Treatment of Depression in Elderly Patients With and Without Dementia Disorders

Cited by 52 publications

References 0 publications

Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication

Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication

The prevalence, diagnosis and treatment of depression in dementia patients in chronic care facilities in the last six months of life

Cholinergic deficits contribute to behavioral disturbance in patients with dementia

Contact Info

Product

Resources

About